We recently published our article 5 Stocks Under $10 Analysts Believe Could Soar 200%. To read the full story, you can go directly to 10 Stocks Under $10 Analysts Believe Could Soar 200%. In this article, we discuss Lexeo Therapeutics Inc. (NASDAQ:LXEO) as one of the stocks gaining attention, and here’s a closer look at why it stands out in today’s market.

Stocks trading below $10 have always attracted investors looking for outsized returns. The appeal is easy to understand: a stock rising from $5 to $15 delivers a 200% gain, meaning the investment triples in value. However, a low share price does not automatically mean a company is cheap.

One useful piece of market trivia is that share price and company size are not the same thing. A stock trading at $6 can still represent a multibillion-dollar business if the company has hundreds of millions of shares outstanding. That is why investors searching for the best stocks under $10 should also examine market capitalization, revenue growth, profitability, debt, cash flow, and long-term business prospects.

The companies featured in this article are not small penny stocks. Each has a market capitalization of more than $2 billion and carries a consensus analyst price target suggesting at least 200% upside.

Small-Cap Stocks Are Gaining Momentum

The search for 10 stocks under $10 that could soar 200% comes as smaller companies begin outperforming the broader U.S. stock market.

On July 2, Dominic Pappalardo, Chief Multi-Asset Strategist at Morningstar Wealth, said small-cap stocks could continue delivering above-market returns because their valuations remain attractive compared with large-cap shares.

During 2026, the Morningstar U.S. Small Cap Market Index gained 14%, outperforming the 10.7% increase recorded by the broader Morningstar U.S. Market.

This performance is notable because U.S. small-cap stocks have generally lagged their mid-cap and large-cap peers over the past 15 years. That prolonged underperformance has left many smaller companies trading at discounted valuations, creating potential opportunities for investors looking for undervalued stocks under $10.

The small-cap rally has continued despite a volatile year shaped by geopolitical tensions, including the Iran-U.S. conflict. Latin American stocks have also performed well since the beginning of the war, supported partly by the region’s exposure to oil and other commodities.

Small Caps May Offer Better Diversification

Pappalardo also pointed to diversification as another reason investors may consider small-cap stocks.

Although the S&P 500 includes around 500 companies, approximately 40% of the index is concentrated in its 10 largest holdings. This means a relatively small group of mega-cap companies can have an enormous influence on the performance of the broader market.

Small-cap indexes are generally less concentrated. Their performance is spread across a wider range of industries, including healthcare, financial services, industrials, energy, consumer products, and technology.

This broader exposure could appeal to investors who believe the market has become too dependent on a handful of large technology companies. It may also create opportunities to find high-upside stocks under $10 that are overlooked by investors focused primarily on the biggest names on Wall Street.

Why Stocks Under $10 Can Produce Large Returns

Low-priced stocks can generate dramatic percentage gains because even a relatively small dollar increase can translate into a large return.

For example, a stock rising from $3 to $6 doubles in value. If it reaches $9, it produces a 200% gain. However, the same mathematics also works in reverse. A decline from $6 to $3 results in a 50% loss.

That is why stocks with triple-digit upside potential usually come with considerable risk. A depressed stock price may reflect temporary market pessimism, but it can also signal weak earnings, high debt, slowing demand, regulatory problems, or uncertainty surrounding the company’s business model.

Analyst price targets should therefore be treated as research tools rather than guarantees. A consensus estimate showing 200% upside means analysts see significant recovery potential, but the company may still need to meet ambitious revenue, earnings, or operational expectations.

Small-Cap Valuations Remain Appealing

Morningstar Wealth believes small-cap stocks are more undervalued than they have been in years, while large-cap stocks currently appear expensive.

That valuation gap could support further gains if investors begin shifting money away from highly valued mega-cap stocks and toward smaller companies with stronger recovery potential.

Still, not every inexpensive stock will become a winner. The strongest opportunities may be found in companies with improving fundamentals, manageable debt, competitive advantages, and identifiable growth catalysts.

With that background, let’s examine the 10 stocks under $10 that could soar 200%.

CHECK THIS OUT: Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years andTop 10 Cheap Stocks Under $10 To Buy Now.

Our Methodology

In order to come up with our list of the 10 stocks under $10 that could soar 200%, we screened U.S.-listed stocks trading below $10 with market capitalizations above $2 billion, shortlisted those with at least 200% consensus upside as of the July 10 close, and ranked the 10 qualifying companies in ascending order based on their projected upside.

5 Stocks Under $10 Analysts Believe Could Soar 200%

4. Lexeo Therapeutics Inc. (NASDAQ:LXEO)

Lexeo Therapeutics Inc. (NASDAQ: LXEO) takes the number four position among the 10 best stocks under $10 that could triple, with shares recently trading at approximately $4.68 after rising 2.63%. The company is developing genetic medicines for serious inherited disorders, with particular attention being placed on LX2006, its investigational gene therapy for Friedreich’s ataxia cardiomyopathy.

On June 15, Lexeo Therapeutics Inc. (NASDAQ: LXEO) announced that it had finalized the pivotal trial protocol for SUNRISE-FA 2. The company also completed the statistical analysis plan intended to generate the clinical evidence required to support a future Biologics License Application with the U.S. Food and Drug Administration.

Finalizing a pivotal study protocol is an important milestone for any clinical-stage biotechnology company. Early-stage studies are generally designed to examine safety, dosing, biological activity, and preliminary signs of efficacy. A pivotal trial, by comparison, is constructed with the expectation that its results may form the foundation of an eventual regulatory submission.

The trial protocol establishes the structure of the study, including the patient population, treatment schedule, primary and secondary endpoints, monitoring procedures, safety assessments, and other essential components. The statistical analysis plan determines how the resulting data will be examined and what standards must be met to support the conclusions.

Lexeo Therapeutics Inc. (NASDAQ: LXEO) said the program is being developed under a pathway targeting a potential 2028 approval for LX2006. Although the timeline remains subject to successful patient enrollment, trial execution, data quality, and regulatory review, the completed study design provides investors with a clearer picture of the company’s intended development schedule.

LX2006 is an AAVrh10-based gene therapy being evaluated for Friedreich’s ataxia-associated cardiomyopathy. Friedreich’s ataxia is a rare inherited disorder caused by mutations that lead to inadequate production of frataxin, a protein important for proper mitochondrial function.

The disease affects the nervous system and can produce progressive problems involving movement, coordination, balance, speech, and muscle function. Cardiac involvement is particularly serious because many patients develop cardiomyopathy, a condition in which the heart muscle becomes weakened, thickened, or otherwise unable to function normally.

For patients with Friedreich’s ataxia, cardiac complications can become one of the most dangerous aspects of the disease. Existing treatment options may help manage certain symptoms, but there remains a need for therapies capable of addressing the underlying genetic and biological causes of the heart damage.

Lexeo Therapeutics Inc. (NASDAQ: LXEO) is attempting to use gene delivery to introduce a functional genetic sequence into targeted tissues. The goal is to improve frataxin expression within the heart and potentially slow, stabilize, or reverse aspects of Friedreich’s ataxia cardiomyopathy.

Chief Medical Officer Narinder Bhalla, M.D., described the completion of the SUNRISE-FA 2 study design as a major development for the LX2006 program. He emphasized that patients with Friedreich’s ataxia, particularly those suffering from cardiac involvement, continue to face a substantial unmet need for new treatment options.

Management’s next major operational objective is to begin the pivotal study and enroll the first patient. Patient enrollment can be one of the most challenging parts of rare-disease drug development. Because the eligible population is relatively small and often geographically dispersed, companies must work with specialized treatment centers, physicians, patient organizations, and families to identify suitable participants.

Gene therapy trials may also involve extensive screening and monitoring requirements. Patients and physicians must understand both the potential benefits and the uncertainties associated with administering a treatment that introduces genetic material into the body.

On June 25, JPMorgan lowered its price target for Lexeo Therapeutics Inc. (NASDAQ: LXEO) from $12 to $9. Although the target was reduced, the new estimate still represented potential upside of more than 92% from the referenced share price.

JPMorgan maintained an Overweight rating on Lexeo Therapeutics Inc. (NASDAQ: LXEO), indicating that the firm continued to expect the stock to outperform despite using more conservative assumptions in its updated valuation model. The revised target incorporated the company’s latest clinical and operational developments.

An analyst price-target reduction should not automatically be treated as a negative verdict on the company. In biotechnology, target changes can reflect shifting timelines, updated probabilities of clinical success, changes in expected research spending, dilution assumptions, or broader market conditions. JPMorgan’s decision to preserve an Overweight rating suggests that it continues to see favorable risk-reward potential in Lexeo Therapeutics Inc. (NASDAQ: LXEO).

Still, investors should recognize that a 2028 approval pathway places the company’s primary value-creation event several years into the future. Between now and then, Lexeo Therapeutics Inc. (NASDAQ: LXEO) must enroll patients, conduct the study, collect and analyze the data, maintain manufacturing consistency, communicate with regulators, and secure enough funding to support its operations.

Gene therapy development also carries unique safety and regulatory challenges. The treatment may be administered only once, making accurate dosing and manufacturing quality essential. Regulators will closely examine immune reactions, liver-related effects, durability of expression, cardiovascular outcomes, and any unexpected complications.

Lexeo Therapeutics Inc. (NASDAQ: LXEO) is a clinical-stage biotechnology company developing genetic medicines for serious inherited conditions. In addition to LX2006, the company is developing LX2020, another gene-therapy candidate designed to deliver genetic material to heart muscle.

The company’s focus on cardiac genetic diseases could create a differentiated position within the biotechnology industry. Many gene-therapy companies initially targeted diseases involving the blood, liver, muscles, or central nervous system. The successful delivery of genetic medicines to the heart could open opportunities across several severe inherited cardiovascular disorders.

However, scientific potential does not always translate into commercial success. Even a therapy that produces encouraging clinical data must eventually receive regulatory approval, achieve reimbursement, gain physician acceptance, and demonstrate that it can be manufactured and delivered reliably.

Lexeo Therapeutics Inc. (NASDAQ: LXEO) is therefore one of the more intriguing gene-therapy stocks under $5, but it is also one of the more speculative names in this countdown. Its current market valuation could rise significantly if LX2006 generates strong pivotal data and moves toward approval.

For investors searching for the best biotech stocks under $10, gene-therapy stocks with high upside, rare-disease stocks to watch, and small-cap stocks that could become multibaggers, Lexeo Therapeutics Inc. (NASDAQ: LXEO) offers a promising but long-duration investment thesis. Its success will depend on whether the company can turn an ambitious genetic-medicine platform into convincing clinical evidence for patients with Friedreich’s ataxia cardiomyopathy.

YOU MUST READ THIS: 10 Robotics Stocks to Buy Now as Amazon (AMZN) Hits 1M Robots

Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.